CNS Cancers

Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma

The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII...

Neuroendocrine Tumors

Health-Related Quality of Life in Everolimus-Treated Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel and colleagues, no significant difference in deterioration of health-related quality of life was observed with everolimus...

Hepatobiliary Cancer

Individualized Adaptive Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors

In a single-center phase II study reported in JAMA Oncology, Feng and colleagues found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control...


More Top Stories

Pancreatic Cancer

Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study

Solid Tumors
Breast Cancer

I’m Not a Victim of Cancer

What I thought after feeling a large, hard lump—similar to the feel of a granola bar—in my left breast was that I probably pulled a muscle while playing with my two young children, ages 7 and 5. Cancer never entered my mind until I asked my husband to feel the lump, and he immediately said, with...


U.S. Incidence and Projected Rise of Merkel Cell Carcinoma

The number of U.S. cases of Merkel cell carcinoma is rising about six times faster than most other cancers, and at nearly twice the rate of melanoma. Paulson et al reported these findings in The Journal of the American Academy of Dermatology, which are based on research conducted at the University...

Bladder Cancer

Thomas Powles, MD, on Urothelial Carcinoma: Results From the IMvigor211 Trial

Breast Cancer

Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?

THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.1  “At this time point, our study showed no difference in disease-free survival or overall survival between 5...

CancerLinQ LLC Partners With the National Society of Genetic Counselors

CancerLinQ LLC and the National Society of Genetic Counselors (NSGC), the professional society for genetic counselors, announced that they have entered into a strategic alliance. With the collaboration, NSGC leaders and members will provide expertise to CancerLinQ®, ASCO’s health information...

Serum Bone Biomarkers in Early Breast Cancer and Risk of Bone Metastasis

In a study reported in the Journal of the National Cancer Institute, Brown et al found that the serum bone biomarkers P1NP, CTX, and 1-CTP showed good prognostic ability for bone metastasis in patients in the phase III AZURE (BIG01/04) trial of adjuvant zoledronic acid in early breast cancer....

Bladder Cancer

Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Results From the CheckMate 032 Trial

Solid Tumors
Gastrointestinal Cancer

FDA Approves Radiopharmaceutical for Rare Gastrointestinal Cancers

On January 26, 2018, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug is indicated for adult patients with somatostatin receptor–positive GEP-NETs. GEP-NETs can be...


Dose Rounding of Anticancer Agents: Hematology/Oncology Pharmacy Association Position Statement

As reported in the Journal of Oncology Practice by Fahrenbruch et al, the Hematology/Oncology Pharmacy Association (HOPA) has issued a position statement on dose rounding of biologic and cytotoxic anticancer agents. To formulate the position statement, the HOPA standards committee organized a work ...